home / stock / idya / idya message board
Subject | By | Source | When |
---|---|---|---|
$THER STOCK CANCER GOOD NEWS | Jayzp | investorshub | 04/24/2023 12:39:39 PM |
Finally some pub. Just take something to | Poshfox | investorshub | 09/02/2020 10:49:52 PM |
$60 million becomes $100 offering. | Laster | investorshub | 06/18/2020 2:07:55 AM |
POS company gets $100 million and then announces | Laster | investorshub | 06/17/2020 12:26:28 AM |
Awesome press release, lets see where this goes | dinogreeves | investorshub | 06/16/2020 12:19:43 PM |
We have made significant progress on our Phase | xr_biotech_consult | investorshub | 11/13/2019 8:42:45 PM |
IDEAYA anticipates that existing cash, cash equivalents and | xr_biotech_consult | investorshub | 11/13/2019 8:39:51 PM |
has anyone bought except me? big day today | xr_biotech_consult | investorshub | 11/13/2019 7:31:14 PM |
spec. buy | xr_biotech_consult | investorshub | 11/05/2019 5:47:08 PM |
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and dev...
IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study PR Newswire Oral presentation at ASCO 2024 scheduled for Monday, June 3, 2024 , at 9:51 AM CDT The abstract summary wil...
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer PR Newswire Selected a move-forward Phase 2 expansion dose for IDE397 monotherapy in MTAP-deletion squamous NSCLC, based on...